Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells $63,825.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 851 shares of the company’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $75.00, for a total value of $63,825.00. Following the transaction, the insider directly owned 52,173 shares in the company, valued at $3,912,975. This trade represents a 1.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total value of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The shares were sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Stock Performance

Disc Medicine stock opened at $76.26 on Friday. The company has a market cap of $2.91 billion, a PE ratio of -11.52 and a beta of 0.97. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The company’s 50-day moving average is $69.23 and its two-hundred day moving average is $70.39.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Equities analysts anticipate that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Disc Medicine by 22.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock valued at $756,000 after purchasing an additional 2,807 shares in the last quarter. Millennium Management LLC boosted its position in shares of Disc Medicine by 1,277.1% during the first quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after purchasing an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Disc Medicine by 3.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock worth $4,793,000 after purchasing an additional 3,454 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Disc Medicine by 18.0% in the 2nd quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock valued at $1,276,000 after buying an additional 3,682 shares during the period. Finally, Invesco Ltd. grew its holdings in shares of Disc Medicine by 21.6% in the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock valued at $891,000 after buying an additional 2,983 shares during the period. Institutional investors own 83.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on IRON. Wedbush reaffirmed an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Morgan Stanley increased their price target on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, June 15th. Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Disc Medicine currently has an average rating of “Moderate Buy” and an average target price of $104.44.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.